论文部分内容阅读
对于Ⅰ型糖尿病 (胰岛素依赖型 )病人胰岛素的缺乏和高血糖症会导致脂质代谢异常。糖尿病肾病是Ⅰ型糖尿病并发冠心病的主要风险因子。Ⅱ型糖尿病 (非胰岛素依赖型 )经常发生异常脂质代谢。高胆固醇血症同样也普遍存在于非糖尿病人群中 ,但发生冠心病的相对风险随胆固醇水平的升高而升高。基于效率、耐受性和临床试验结果 ,HMG CoA还原酶抑制剂是降低LDL胆固醇水平的首选药物。如果糖尿病患者以高甘油三酯为主要症状 ,用纤维酸衍生物进行治疗比较合理。在Ⅰ型糖尿病尤其是Ⅱ型糖尿病中 ,脂质异常可显著增加大血管并发症 ,尤其是增加冠心病的发生率。尽管两种类型的糖尿病均以脂质代谢异常为主要表现 ,但两种糖尿病异常脂质代谢本质不同 ,因此治疗方法也各异。
Insulin deficiency and hyperglycemia in patients with type 1 diabetes (insulin-dependent) result in dyslipidemia. Diabetic nephropathy is a major risk factor for type 1 diabetes complicated by coronary heart disease. Type II diabetes (non-insulin-dependent) often have abnormal lipid metabolism. Hypercholesterolemia is also common in nondiabetic patients, but the relative risk of coronary heart disease increases with increasing cholesterol levels. Based on efficiency, tolerability and clinical trial results, HMG CoA reductase inhibitors are the drug of choice for lowering LDL cholesterol levels. If diabetic patients with high triglycerides as the main symptom, with fibric acid derivatives for treatment is more reasonable. In type I diabetes, especially in type II diabetes, lipid abnormalities can significantly increase macrovascular complications, especially increasing the incidence of coronary heart disease. Although both types of diabetes are characterized by lipid metabolism abnormalities, the two lipid abnormalities of diabetes mellitus are of different essences and the treatment methods are also different.